Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease.
This randomized, open-label study compared the cost efficiency of low-dose pravastatin combined with low-dose cholestyramine with high-dose pravastatin monotherapy in 59 patients with moderate hypercholesterolemia and coronary disease. Both regimes were effective in improving lipid profiles in these patients; however, low-dose combination therapy enhanced achievement in therapeutic goals and cost efficiency.
Ito
M K
MK
Department of Pharmacy Practice, University of the Pacific School of Pharmacy, Stockton, California, USA.
Shabetai
R
R
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D002792:Cholestyramine Resin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D003327:Coronary Disease / Q000150:complications*; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D014280:Triglycerides; D002792:Cholestyramine Resin; D017035:Pravastatin